1.Current status and progress in gastric cancer with liver metastasis.
Chinese Medical Journal 2011;124(3):445-456
OBJECTIVEThis review discusses the current status and progress in studies on gastric cancer with liver metastasis (GCLM), involving the routes, subtypes, and prognosis of GCLM; the genes and molecules associated with metastasis; the feasibility and value of each imaging modality; and current treatment options.
DATA SOURCESThe data used in this review were mainly from Medline and PubMed published in English from 2005 to August 2010. The search terms were "gastric cancer" and "liver metastasis".
STUDY SELECTIONArticles regarding the characteristics, diagnostic modalities, and various therapeutic options of GCLM were selected.
RESULTSThe prognosis of GCLM is influenced by the clinicopathological characteristics of primary tumors, as well as the presence of liver metastases. Improved understanding of related genes and molecules will lead to the development of methods of early detection and targeted therapies. For the diagnosis of GCLM, each imaging modality has its relative benefits. There remains no consensus regarding therapeutic options.
CONCLUSIONSEarly detection and characterization of liver metastases is crucial for the prognosis of gastric cancer patients. Multidisciplinary team discussions are required to design optimal treatment strategies, which should be based on the clinicopathological characteristics of each patient.
Humans ; Liver Neoplasms ; diagnosis ; drug therapy ; secondary ; surgery ; Stomach Neoplasms ; complications ; diagnosis ; drug therapy ; surgery
2.Gastric Metastasis of Hepatocellular Carcinoma Treated by Transarterial Chemoembolization: A Case Report.
Ji Hoon KIM ; Joong Won PARK ; Joon Il CHOI ; Hyun Beom KIM ; Dong Wook KOH ; Woo Jin LEE ; Chang Min KIM
The Korean Journal of Hepatology 2007;13(1):91-95
Extrahepatic metastasis in patients with hepatocellular carcinoma (HCC) occurs frequently. The most common site of metastasis is the lung, followed by regional lymph nodes and bones. However, gastrointestinal metastasis of HCC is a rare condition and solitary polypoid metastatic lesion on stomach without any evidence of direct invasion from primary mass is very rare. These metastatic lesions are usually asymptomatic, and most are discovered at postmortem examination or are found incidentally during laparotomy. The choice of treatment for gastrointestinal metastatic lesion of HCC includes surgery, transarterial chemoembolization, and local injection but the treatment is often difficult and unsuccessful. We report a case of 69 years old man who presented disappearance of a polypoid metastatic lesion of HCC on the gastric fundus by transarterial chemoembolization.
Aged
;
Carcinoma, Hepatocellular/*diagnosis/secondary/therapy
;
*Chemoembolization, Therapeutic
;
Duodenoscopy
;
Gastric Fundus/radiography
;
Humans
;
Liver Neoplasms/*diagnosis/pathology/therapy
;
Male
;
Stomach Neoplasms/*diagnosis/secondary/therapy
;
Tomography, X-Ray Computed
3.Adenocarcinoma of Lung Cancer with Solitary Metastasis to the Stomach.
The Korean Journal of Gastroenterology 2014;64(3):154-157
Although hematogenous metastasis of cancer to the gastrointestinal track is rare, it sometime has been reported in patients with malignant melanoma and breast cancer. However, it is extremely rare for lung cancer to metastasize to the stomach, not to mention solitary gastric metastasis. Herein, the authors report a case of a 69-year-old man who was initially diagnosed with lung cancer with synchronous primary gastric cancer which proved to be lung cancer with solitary gastric metastasis after the operation.
Adenocarcinoma/*diagnosis/pathology
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Diagnosis, Differential
;
Endoscopy, Digestive System
;
Humans
;
Lung Neoplasms/*diagnosis/drug therapy/pathology
;
Male
;
Stomach Neoplasms/*diagnosis/secondary/surgery
;
Tomography, X-Ray Computed
4.A Case of Advanced Gastric Cancer Presenting as Multiple Colonic Lymphoid Hyperplasia.
In Hee LEE ; Jieun LEE ; Seong Wook BYEON ; Heejung LEE ; Solmi HUO ; Seung Bae YOON ; Jin Su KIM ; Sung Hak LEE ; Sang Young ROH
The Korean Journal of Gastroenterology 2015;66(4):221-226
Gastric cancer frequently disseminates to the liver, lung, and bone via hematogeneous, lymphatic, or peritoneal routes. However, gastric adenocarcinoma that metastasize to the colon and that shows typical linea platisca pattern on colonofiberscopy has rarely been reported. Recently, the authors experience a case of advanced gastric cancer with colonic metastases in a 55-year-old female patient. Multiple colonic lymphoid hyperplasias were detected on colonofiberscopy and biopsy revealed metastatic gastric cancer to the colonic wall. She was treated with mFOLFOX (5-FU, oxaliplatin, leucovorin) and has achieved stable disease status without disease progression. Herein, we report a rare case of signet ring-cell gastric cancer which metastasized to the colon in the form of multiple colonic lymphoid hyperplasias.
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Colonic Neoplasms/*diagnosis/secondary
;
Colonoscopy
;
Female
;
Fluorouracil/administration & dosage
;
Gastroscopy
;
Humans
;
Hyperplasia/diagnosis
;
Leucovorin/administration & dosage
;
Middle Aged
;
Organoplatinum Compounds/administration & dosage
;
Positron-Emission Tomography
;
Stomach Neoplasms/*diagnosis/drug therapy
;
Tomography, X-Ray Computed
5.Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Xiao-Ming DU ; Liu-Hua WANG ; Xiao-Wen CHEN ; Yi-Xiao LI ; Yu-Cong LI ; Yu-Wen CAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(3):305-312
The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04-2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30-3.22), colorectal cancer (HR=1.40, 95% CI=1.04-1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12-2.89), for Europeans (HR=1.98, 95% CI=1.44-2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10-2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25-2.77) and poor differentiation (OR=1.88, 95% CI=1.14-3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.
Antineoplastic Agents
;
therapeutic use
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Colorectal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Esophageal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Gastrointestinal Tract
;
metabolism
;
pathology
;
Gene Expression
;
Humans
;
Neoadjuvant Therapy
;
methods
;
Neoplasm Grading
;
Neoplasms, Vascular Tissue
;
diagnosis
;
drug therapy
;
mortality
;
secondary
;
Prognosis
;
SOXB1 Transcription Factors
;
genetics
;
metabolism
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Survival Analysis
6.Diagnosis and management of metastatic pancreatic tumors.
Dong-kui XU ; Ping ZHAO ; Yong-fu SHAO ; Cheng-feng WANG ; Hong-wei LIN ; Yan-tao TIAN ; Yue-min SUN
Chinese Journal of Oncology 2006;28(4):306-308
OBJECTIVETo study the clinicopathological features and prognostic factors of metastatic pancreatic tumor.
METHODSThe clinical data of 18 metastatic pancreatic tumors were retrospectively analyzed. The primary foci of these 18 patients included: 8 lung cancer, 2 gastric cancer, and malignant histiocytoma, melanoma, rectal cancer, thyroid cancer, renal cell carcinoma, esophageal carcinoma, liver cancer and ovarian cancer each.
RESULTSAll these 18 patients harboring metastatic pancreatic tumor did not show any specific symptoms but were frequently found to have a solitary (14 cases) or multiple (4 cases) homogeneous and hypodense nodules on CT scan without any enhancement except one metastatic renal cell carcinoma. The diagnosis was cytologically confirmed in 14 patients by fine needle aspiration biopsy guided by CT or ultrasonography, and diagnosed by postoperative pathology in the other 4 patients. After receiving combined modality treatment, their survival time was 8 to 38 months with an average of 19 months.
CONCLUSIONMetastatic pancreatic tumors are rare and give no specific symptom or image finding. Selection of appropriate combined modality treatment according to the type of primary focus is very important for the management.
Adult ; Aged ; Biopsy, Fine-Needle ; Carcinoma, Small Cell ; diagnosis ; secondary ; therapy ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms ; pathology ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Pancreatic Neoplasms ; diagnosis ; secondary ; therapy ; Prognosis ; Retrospective Studies ; Stomach Neoplasms ; pathology ; Tomography, X-Ray Computed
7.Gastric Metastasis from Breast Cancer.
The Korean Journal of Gastroenterology 2013;61(1):54-57
No abstract available.
Adenocarcinoma/*diagnosis/radiography/secondary
;
Adult
;
Antineoplastic Agents/therapeutic use
;
Breast Neoplasms/*diagnosis/drug therapy/pathology
;
Carrier Proteins/metabolism
;
Doxorubicin/therapeutic use
;
Drug Therapy, Combination
;
Endoscopy, Digestive System
;
Female
;
Glycoproteins/metabolism
;
Humans
;
Mastectomy, Modified Radical
;
Positron-Emission Tomography and Computed Tomography
;
Stomach Neoplasms/*diagnosis/radiography/secondary
;
Taxoids/therapeutic use
;
Tomography, X-Ray Computed
8.Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction.
Seung Jae HWANG ; Jong Won PARK ; Sehe Dong LEE ; Gyong Jung KIM ; Cheol Ho SIN ; Seung Hyun NAM ; Bong Seog KIM
The Korean Journal of Internal Medicine 2006;21(4):252-255
Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both capecitabine and oxaliplatin have been well tolerated as single agents for patients with severe hepatic dysfunction, the combination of these drugs has not been investigated. We report here on a case of successful treatment of a patient suffering with severe liver dysfunction and metastatic gastric cancer; the patient was treated with a combination of capecitabine and oxaliplatin (XELOX). The initial bilirubin level of the patient was 10.9 mg/dL. After two cycles of treatment, his bilirubin level decreased to 2.1 mg/dL. He has experienced an excellent radiological response and he has received six cycles of XELOX chemotherapy. XELOX chemotherapy is feasible and it can be associated with positive outcomes for the patients suffering with metastatic gastric cancer and severe liver dysfunction.
Stomach Neoplasms/complications/*pathology/surgery
;
Prodrugs
;
Organoplatinum Compounds/*therapeutic use
;
Middle Aged
;
Male
;
Liver Neoplasms/complications/*drug therapy/secondary
;
Liver Function Tests
;
Liver Failure/diagnosis/drug therapy/*etiology
;
Humans
;
Gastrectomy
;
Follow-Up Studies
;
Fluorouracil/*analogs & derivatives/therapeutic use
;
Drug Therapy, Combination
;
Deoxycytidine/*analogs & derivatives/therapeutic use
;
Antineoplastic Agents/*therapeutic use
;
Adenocarcinoma/complications/secondary/*therapy
9.Strategies of diagnosis and treatment for peritoneal metastasis of gastric cancer.
Chinese Journal of Gastrointestinal Surgery 2017;20(5):500-503
Peritoneal metastasis of gastric cancer is the main cause of death in gastric cancer patients. Peritoneal metastasis of gastric cancer is difficult to diagnose in its early stage due to lack of obvious clinical signs and symptoms, and poor treatment outcomes and prognosis are often associated with late stage peritoneal metastasis. Therefore, it is crucial to utilize effective early diagnostic tools and to improve the long-term outcomes and the prognosis of patients with advanced gastric cancer. Recently, systemic chemotherapy and intraperitoneal chemotherapy are the first line therapy, and cytoreductive operation plus abdominal cavity thermochemotherapy may be the best method in the treatment of peritoneal metastasis. However, conversion therapy has been gradually incorporated into the treatment of peritoneal metastasis of gastric cancer because of the better efficacy and the higher survival.
Antineoplastic Agents
;
therapeutic use
;
Antineoplastic Protocols
;
Combined Modality Therapy
;
methods
;
Cytoreduction Surgical Procedures
;
Early Detection of Cancer
;
methods
;
Humans
;
Hyperthermia, Induced
;
Peritoneal Neoplasms
;
diagnosis
;
secondary
;
Prognosis
;
Stomach Neoplasms
;
mortality
;
pathology
;
Treatment Outcome
10.Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Joon Seong AHN ; Ja Ryong JEON ; Hong Seok YOO ; Taek Kyu PARK ; Cheol Keun PARK ; Dong Hyun SINN ; Seung Woon PAIK
Clinical and Molecular Hepatology 2013;19(2):173-178
Hepatoid adenocarcinoma (HAC) is a rare type of extrahepatic carcinoma whose morphology is similar to that of hepatocellular carcinoma (HCC). Metachronous HCC and HAC in the same patient is extremely rare. The case of a 68-year-old man with chronic hepatitis B infection who had both HCC and HAC of the stomach is reported herein. Nine years previously this patient had been diagnosed with HCC and received a right lobectomy. HCC that recurred at the caudate lobe at 6 months after the operation was successfully treated with transarterial chemoembolization. The patient was followed up regularly thereafter without evidence of tumor recurrence for 9 years. In July 2010 his serum alpha-fetoprotein (AFP) level elevated from 6.5 ng/mL to 625.4 ng/mL, and he developed a probable single metastatic lymph node around the hepatic artery without intrahepatic lesions. Subsequent evaluation with upper endoscopy revealed a 4-cm ulcerative lesion on the antrum of the stomach. Subtotal gastrectomy was performed with lymph-node dissection. Histologic examination revealed a special type of extrahepatic AFP-producing adenocarcinoma-HAC with lymph-node metastasis-which indicates that HAC can be a cause of elevated AFP even in patients with HCC. HAC should be considered if a patient with stable HCC exhibits unusual elevation of AFP.
Adenocarcinoma/*diagnosis/drug therapy/secondary
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Camptothecin/analogs & derivatives/therapeutic use
;
Carcinoma, Hepatocellular/*diagnosis/drug therapy/pathology
;
Chemoembolization, Therapeutic
;
Chemotherapy, Adjuvant
;
Fluorouracil/therapeutic use
;
Gastroscopy
;
Humans
;
Leucovorin/therapeutic use
;
Liver Neoplasms/*diagnosis/drug therapy/pathology
;
Lymph Nodes/surgery
;
Lymphatic Metastasis
;
Male
;
Recurrence
;
Silicates/therapeutic use
;
Stomach Neoplasms/*diagnosis/drug therapy/secondary
;
Titanium/therapeutic use
;
Tomography, X-Ray Computed
;
alpha-Fetoproteins/*analysis